Phillips-Medisize
Phillips-Medisize is a privately held CDMO founded in 1964, designing and manufacturing drug delivery devices, medtech components, and IVD products for 80% of Top 10 pharma and 100% of Top 10 med device companies across 30 global sites.
- Company typePrivate
- Founded1964
- HeadquartersHudson, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Phillips-Medisize does
Phillips-Medisize is a privately held contract development and manufacturing organization (CDMO) founded in 1964 and headquartered in Hudson, Wisconsin. The company designs and manufactures drug delivery devices, medical technology components, and in vitro diagnostic products for pharmaceutical, medtech, and IVD customers worldwide. It serves 80% of the Top 10 valuable pharmaceutical companies, 100% of the Top 10 medical device companies, and operates from 30 locations across 11 countries with 6,500+ employees, 23 production facilities, and 3M+ sq ft of manufacturing space including 490K+ sq ft of Class 7/8 cleanrooms.
The company's product portfolio spans proprietary platform devices and custom manufacturing services. Pharmaceutical platform products include the Aria Smart Autoinjector (reusable electromechanical device with disposable cassettes and Bluetooth connectivity), Envoi Pen Injector (for insulin and GLP-1 delivery), Dry Powder Inhalers including the Open-Inhale-Close DPI and GyroHaler, Pressurized Metered-Dose Inhalers, and the FOX Vibrating Mesh Nebulizer. MedTech offerings include EdgeStack and TheraVolt medical connectors, Polymicro optical fibers, Polyguide laser delivery systems, Fiberguide components, and capillary tubing. Underlying capabilities include advanced injection molding (plastic, metal, magnesium thixomolding), drug and reagent handling, electronics integration, and specialty fiber optics. The 2025 acquisition of Vectura Group from Philip Morris International significantly expanded inhalation drug delivery capabilities, adding 13 launched products and 25+ years of formulation expertise.
Phillips-Medisize operates a B2B contract-based revenue model with quote-based pricing tailored to individual customer requirements. Revenue is generated from contract manufacturing services, design and development services, and proprietary platform product sales. The company is a wholly owned subsidiary of Molex, which is owned by Koch Inc., providing substantial financial backing and long investment horizons. Pricing is not publicly disclosed, but customer relationships are anchored by long-term, deeply integrated programs (e.g., Exact Sciences scaling from one manual line to three high-volume lines for colon cancer screening kits). The company holds ISO 13485, FDA 21 CFR 820, EU MDR, MDSAP, IATF 16949, and ITAR certifications across its global operations, supporting a unified Quality Management System.
Phillips-Medisize firmographics
Firmographics- Name
- Phillips-Medisize
- Legal name
- Phillips Medisize
- Website
- https://phillipsmedisize.com
- Company type
- Private
- Founded year
- 1964
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Phillips-Medisize is a privately held CDMO founded in 1964, designing and manufacturing drug delivery devices, medtech components, and IVD products for 80% of Top 10 pharma and 100% of Top 10 med device companies across 30 global sites.
- Ownership category
- akta.pro rank
Phillips-Medisize industry classification
Industry- Product category
- Medical Device Contract Manufacturing
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)
Keywords
Where Phillips-Medisize is headquartered
LocationHeadquarters
- HQ city
- Hudson
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Phillips-Medisize business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Phillips Medisize generates revenue primarily through contract manufacturing services as a CDMO. The company designs and manufactures drug delivery systems, medical devices, and diagnostic tools for pharmaceutical, medtech, and IVD customers. Revenue is generated from small volumes to high-volume production in the hundreds of millions of units.
- Design and Development Services: The company provides design and development services including R&D, engineering, and regulatory support. Services span from concept to delivery, covering design strategy, prototyping, clinical trial production, and scaled manufacturing.
- Platform Product Sales: Sale of proprietary platform products including the Envoi pen injector, Aria smart autoinjector, DPI devices, and vibrating mesh nebulizers. These are customizable platform products that accelerate development timelines for biopharma customers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Phillips-Medisize product offering
Product offeringCore offering
Phillips-Medisize is a contract development and manufacturing organization (CDMO) that designs, develops, and manufactures drug delivery devices, medical devices, in vitro diagnostic consumables, and specialty fiber-optic components for pharmaceutical, medtech, and IVD companies. The company operates 30 global sites across 11 countries with end-to-end services from concept through commercial production, including proprietary platform products such as autoinjectors, pen injectors, dry powder inhalers, and vibrating mesh nebulizers.
Product overview
Phillips-Medisize is a contract development and manufacturing organization (CDMO) offering a comprehensive portfolio of drug delivery devices, medical technology components, and in vitro diagnostic solutions. The pharmaceutical segment includes platform products such as the Aria Smart Autoinjector (reusable electromechanical device with disposable cassettes), Envoi Pen Injector, Dry Powder Inhalers (OIC, LOMI, GyroHaler), Pressurized Metered-Dose Inhalers, and FOX Vibrating Mesh Nebulizer. The MedTech segment offers medical connectors (EdgeStack, TheraVolt), specialty fiber-optic solutions (Polymicro Optical Fiber, Polyguide Laser Delivery System, Fiberguide components), and capillary tubing products. Additional offerings include VYAFUSER pumps and Breelib inhalation systems. The company leverages 60+ years of experience across 30 global locations with 6,500+ employees, serving pharmaceutical, medtech, and in vitro diagnostic industries.
Differentiator
Problem solved
Functional benefit
Products and services
- Aria Smart Autoinjector
Quantifiable outcome
- 461M+ lifesaving drug delivery devices developed in 2025
- +4 more outcomes
Companies that use Phillips-Medisize
Customer profileNamed customers11 records
Segments4 records
Ideal customer profiles4 records
Phillips-Medisize technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Phillips-Medisize partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- VecturacoreMolex, through its affiliate Molex Asia Holdings, acquired Vectura Group Limited from Philip Morris International subsidiary Vectura Fertin Pharma Inc. The acquisition, completed in 2025, expanded Phillips Medisize's capabilities in inhalation drug delivery and respiratory disease product development. Vectura brought 25+ years of experience, 13 launched products, and expertise in formulation science, device technology, and inhaled medicine solutions.
- MolexcorePhillips Medisize is a Molex company. Molex is a global electronics brand serving many sectors including healthcare. The parent company provides world-class electronics capabilities and interconnect solutions that Phillips Medisize leverages for medical device development and manufacturing.
- KochcoreMolex is owned by Koch Inc., one of the largest privately held companies in the world with annual revenue exceeding $125 billion and 120,000 employees in approximately 50 countries. Koch provides financial backing, stability, and access to the broader Koch family of companies that also serve medical companies.
Scale indicators21 records
Recent moves6 records
Expansion highlights6 records
Phillips-Medisize competitors and assessment
Company assessmentDirect peers
- West Pharmaceutical Services: West Pharmaceutical Services is the most direct comparable to Phillips-Medisize, specializing in drug containment and delivery systems including elastomer components, seals, and injection device platforms (e.g., Daikyo Crystal Zenith, SmartDose). Both companies serve the same Top 10 pharma customer base with combination product CDMO services, making West a close functional peer in primary packaging and drug delivery device manufacturing.
- Stevanato Group: Stevanato Group is an Italian-based direct peer operating in drug containment, drug delivery devices, and diagnostic solutions. The company offers similar capabilities to Phillips-Medisize including glass primary packaging, prefillable syringes, and device development/contract manufacturing services for pharma and diagnostic customers.
- AptarGroup: AptarGroup is a direct peer specializing in drug delivery systems including inhalation devices (pMDI valves, DPI), injectable components (PremiumCoat stoppers), and dispensing solutions for pharma and consumer health. The Pharma division directly competes with Phillips-Medisize's autoinjector, inhaler, and elastomeric component CDMO offerings.
- Gerresheimer: Gerresheimer is a direct peer providing glass and plastic primary packaging, drug delivery devices (autoinjectors, inhalers), and contract manufacturing services for pharmaceutical customers. Its Bormioli Pharma division and high-value solutions segment overlap materially with Phillips-Medisize's drug delivery device CDMO business.
- Catalent: Catalent is a major CDMO peer offering drug development, biologics manufacturing, and drug delivery services including softgel, oral dose, and inhaled formulation capabilities. While broader than Phillips-Medisize in API/finished dose, the inhalation and drug delivery portions compete directly for the same pharma customers.
- SCHOTT Pharma: SCHOTT Pharma manufactures primary packaging (vials, syringes, cartridges) and drug delivery solutions for pharmaceutical companies, with established CDMO capabilities in glass and polymer container systems. The company directly overlaps with Phillips-Medisize in prefillable syringe and cartridge-based device offerings.
- Ypsomed Holding: Ypsomed is a Swiss direct peer specializing in injection and infusion systems including pen injectors, autoinjectors (YpsoMate), and wearable patch injectors. The company serves the same diabetes and biologics drug delivery market as Phillips-Medisize's Envoi and Aria platforms.
Broad incumbents
- Becton, Dickinson and Company (BD): BD is a broad incumbent in medical devices, drug delivery, and diagnostic systems. While BD primarily sells under its own brand, its Medical Pharmaceutical Systems segment competes with Phillips-Medisize in prefilled syringe systems and drug delivery devices for the same pharma customers.
- Baxter International: Baxter is a broad incumbent in medical devices, IV solutions, and drug delivery. The company's Pharmaceuticals and Medical Products segments overlap with Phillips-Medisize's IVD cartridge manufacturing, medical connectors, and injectable drug delivery capabilities.
Emerging players
- Recipharm: Recipharm is a European CDMO peer offering contract development and manufacturing services including inhalation products, injectables, and oral solid dose. While smaller and more focused on traditional dose forms, Recipharm competes with Phillips-Medisize for pharma CDMO contracts particularly in inhalation and sterile fill-finish.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Phillips-Medisize social profiles
Digital presencePhillips-Medisize compliance and trust
Trust signalCompliance12 records
Phillips-Medisize financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phillips-Medisize leadership team
Management profileNumber of profiles
Profiles8 records
Phillips-Medisize subsidiaries and ownership
Company hierarchySubsidiaries1 record
Phillips-Medisize funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phillips-Medisize M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phillips-Medisize
What does Phillips-Medisize do?
Phillips-Medisize is a contract development and manufacturing organization (CDMO) that designs, develops, and manufactures drug delivery devices, medical devices, in vitro diagnostic consumables, and specialty fiber-optic components for pharmaceutical, medtech, and IVD companies. The company operates 30 global sites across 11 countries with end-to-end services from concept through commercial production, including proprietary platform products such as autoinjectors, pen injectors, dry powder inhalers, and vibrating mesh nebulizers.
Is Phillips-Medisize a public or private company?
Phillips-Medisize is a private company. It is classified as corporate owned and is currently operating.
When was Phillips-Medisize founded?
Phillips-Medisize was founded in 1964. It employs 5,001 to 10,000 people.
Where is Phillips-Medisize based?
Phillips-Medisize is headquartered in Hudson, United States, in the North America region.
How does Phillips-Medisize make money?
Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are design and Development Services and platform Product Sales.
Who are Phillips-Medisize's main competitors?
Direct peers on record are West Pharmaceutical Services, Stevanato Group, AptarGroup, Gerresheimer, Catalent, SCHOTT Pharma and Ypsomed Holding. Broad incumbents are Becton, Dickinson and Company (BD) and Baxter International. Recipharm is listed as an emerging player.
Does Phillips-Medisize have an API?
No public API is recorded for Phillips-Medisize.
What industry is Phillips-Medisize in?
Phillips-Medisize's product category is Medical Device Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 339112 and its SIC code is 3841.